Plain-English translation of NCT06204991 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called for patients with advanced melanoma that has not responded to standard immunotherapy. The treatment involves surgically removing a sample of your tumor, growing your immune cells (called tumor-infiltrating lymphocytes) in the laboratory, genetically modifying them to produce a substance that helps them work better, and then infusing these enhanced cells back into your body. The medication is designed to help your own immune system recognize and attack melanoma cells more effectively.
Many melanoma patients stop responding to standard immunotherapy treatments, leaving them without effective options. This medication is being tested because early research suggests that using genetically enhanced immune cells may help patients whose cancers have stopped responding to conventional drugs.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo surgery to remove a tumor sample, which is then sent to the laboratory for cell manufacturing (this takes several weeks). Before receiving the infusion of your enhanced immune cells, you will receive chemotherapy medications to prepare your body. You will then receive an infusion of your genetically modified cells followed by high-dose immune-boosting medication (interleukin-2) given in up to 6 doses. Throughout the study, you will have regular medical visits and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Denmark